Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Spero Therapeutics (SPRO)

Spero Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SPRO
DateTimeSourceHeadlineSymbolCompany
06/03/202413:05GlobeNewswire Inc.Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024NASDAQ:SPROSpero Therapeutics Inc
28/02/202413:05GlobeNewswire Inc.Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial InfectionsNASDAQ:SPROSpero Therapeutics Inc
26/02/202413:05GlobeNewswire Inc.Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare ConferenceNASDAQ:SPROSpero Therapeutics Inc
09/02/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
06/02/202401:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
06/02/202401:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
06/02/202401:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
06/02/202401:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
06/02/202401:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
05/02/202421:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SPROSpero Therapeutics Inc
31/01/202421:05GlobeNewswire Inc.Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SPROSpero Therapeutics Inc
08/01/202411:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
05/01/202413:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
05/01/202413:05GlobeNewswire Inc.Spero Therapeutics Provides Corporate Update and 2024 OutlookNASDAQ:SPROSpero Therapeutics Inc
04/01/202421:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
02/01/202413:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
02/01/202413:05GlobeNewswire Inc.Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract InfectionsNASDAQ:SPROSpero Therapeutics Inc
15/11/202321:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
15/11/202321:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
13/11/202321:50Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SPROSpero Therapeutics Inc
13/11/202321:45Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SPROSpero Therapeutics Inc
13/11/202321:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
13/11/202321:05GlobeNewswire Inc.Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business UpdateNASDAQ:SPROSpero Therapeutics Inc
13/11/202321:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SPROSpero Therapeutics Inc
13/11/202311:45IH Market NewsMonday’s Wall Street Highlights: Boeing, Novo Nordisk, Moody’s, StoneCo, and moreNASDAQ:SPROSpero Therapeutics Inc
06/11/202313:05GlobeNewswire Inc.Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023NASDAQ:SPROSpero Therapeutics Inc
01/11/202320:05GlobeNewswire Inc.Spero Therapeutics to Present at Upcoming November Investor ConferencesNASDAQ:SPROSpero Therapeutics Inc
01/11/202312:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
01/11/202312:05GlobeNewswire Inc.Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business OfficerNASDAQ:SPROSpero Therapeutics Inc
31/10/202320:05GlobeNewswire Inc.Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SPROSpero Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SPRO

Your Recent History

Delayed Upgrade Clock